682 related articles for article (PubMed ID: 33916607)
1. RGD-Binding Integrins Revisited: How Recently Discovered Functions and Novel Synthetic Ligands (Re-)Shape an Ever-Evolving Field.
Ludwig BS; Kessler H; Kossatz S; Reuning U
Cancers (Basel); 2021 Apr; 13(7):. PubMed ID: 33916607
[TBL] [Abstract][Full Text] [Related]
2. Exploring the Role of RGD-Recognizing Integrins in Cancer.
Nieberler M; Reuning U; Reichart F; Notni J; Wester HJ; Schwaiger M; Weinmüller M; Räder A; Steiger K; Kessler H
Cancers (Basel); 2017 Sep; 9(9):. PubMed ID: 28869579
[TBL] [Abstract][Full Text] [Related]
3. Characterisation of a novel, high affinity and selective αvβ6 integrin RGD-mimetic radioligand.
Hall ER; Bibby LI; Slack RJ
Biochem Pharmacol; 2016 Oct; 117():88-96. PubMed ID: 27501918
[TBL] [Abstract][Full Text] [Related]
4. There is a world beyond αvβ3-integrin: Multimeric ligands for imaging of the integrin subtypes αvβ6, αvβ8, αvβ3, and α5β1 by positron emission tomography.
Steiger K; Quigley NG; Groll T; Richter F; Zierke MA; Beer AJ; Weichert W; Schwaiger M; Kossatz S; Notni J
EJNMMI Res; 2021 Oct; 11(1):106. PubMed ID: 34636990
[TBL] [Abstract][Full Text] [Related]
5. Ligands for mapping alphavbeta3-integrin expression in vivo.
Schottelius M; Laufer B; Kessler H; Wester HJ
Acc Chem Res; 2009 Jul; 42(7):969-80. PubMed ID: 19489579
[TBL] [Abstract][Full Text] [Related]
6. Integrin-Targeted Peptide- and Peptidomimetic-Drug Conjugates for the Treatment of Tumors.
Arosio D; Manzoni L; Corno C; Perego P
Recent Pat Anticancer Drug Discov; 2017; 12(2):148-168. PubMed ID: 28164756
[TBL] [Abstract][Full Text] [Related]
7. Human integrin alphavbeta5: homology modeling and ligand binding.
Marinelli L; Gottschalk KE; Meyer A; Novellino E; Kessler H
J Med Chem; 2004 Aug; 47(17):4166-77. PubMed ID: 15293989
[TBL] [Abstract][Full Text] [Related]
8. Radiolabeled Cyclic RGD Peptide Bioconjugates as Radiotracers Targeting Multiple Integrins.
Liu S
Bioconjug Chem; 2015 Aug; 26(8):1413-38. PubMed ID: 26193072
[TBL] [Abstract][Full Text] [Related]
9. Downregulation of the
Roper JA; Wilkinson AL; Gower E; Slack RJ
J Pharmacol Exp Ther; 2021 Feb; 376(2):273-280. PubMed ID: 33318076
[TBL] [Abstract][Full Text] [Related]
10. It's Time to Shift the Paradigm: Translation and Clinical Application of Non-αvβ3 Integrin Targeting Radiopharmaceuticals.
Kossatz S; Beer AJ; Notni J
Cancers (Basel); 2021 Nov; 13(23):. PubMed ID: 34885066
[TBL] [Abstract][Full Text] [Related]
11. Biological and Clinical Consequences of Integrin Binding via a Rogue RGD Motif in the SARS CoV-2 Spike Protein.
Makowski L; Olson-Sidford W; W-Weisel J
Viruses; 2021 Jan; 13(2):. PubMed ID: 33498225
[TBL] [Abstract][Full Text] [Related]
12. Comparison of the RGD Motif-Containing α
Roesch S; Lindner T; Sauter M; Loktev A; Flechsig P; Müller M; Mier W; Warta R; Dyckhoff G; Herold-Mende C; Haberkorn U; Altmann A
J Nucl Med; 2018 Nov; 59(11):1679-1685. PubMed ID: 29674419
[TBL] [Abstract][Full Text] [Related]
13. Arginine-Glycine-Aspartate-Binding Integrins as Therapeutic and Diagnostic Targets.
Sun CC; Qu XJ; Gao ZH
Am J Ther; 2016; 23(1):e198-207. PubMed ID: 24621642
[TBL] [Abstract][Full Text] [Related]
14. The effect of divalent metal cations on the αv integrin binding site is ligand and integrin specific.
Hall ER; Slack RJ
Biomed Pharmacother; 2019 Feb; 110():362-370. PubMed ID: 30529769
[TBL] [Abstract][Full Text] [Related]
15. RGD-based Therapy: Principles of Selectivity.
Rubtsov MA; Syrkina MS; Aliev G
Curr Pharm Des; 2016; 22(7):932-52. PubMed ID: 26648463
[TBL] [Abstract][Full Text] [Related]
16. Potential of Integrin Inhibitors for Treating Ovarian Cancer: A Literature Review.
Kobayashi M; Sawada K; Kimura T
Cancers (Basel); 2017 Jul; 9(7):. PubMed ID: 28698469
[TBL] [Abstract][Full Text] [Related]
17. Fluorescence imaging of invasive head and neck carcinoma cells with integrin αvβ6-targeting RGD-peptides: an approach to a fluorescence-assisted intraoperative cytological assessment of bony resection margins.
Nieberler M; Reuning U; Kessler H; Reichart F; Weirich G; Wolff KD
Br J Oral Maxillofac Surg; 2018 Dec; 56(10):972-978. PubMed ID: 30502043
[TBL] [Abstract][Full Text] [Related]
18. Are Integrins Still Practicable Targets for Anti-Cancer Therapy?
Alday-Parejo B; Stupp R; Rüegg C
Cancers (Basel); 2019 Jul; 11(7):. PubMed ID: 31336983
[TBL] [Abstract][Full Text] [Related]
19. Targeting RGD recognizing integrins: drug development, biomaterial research, tumor imaging and targeting.
Meyer A; Auernheimer J; Modlinger A; Kessler H
Curr Pharm Des; 2006; 12(22):2723-47. PubMed ID: 16918408
[TBL] [Abstract][Full Text] [Related]
20. A Comprehensive Evaluation of the Activity and Selectivity Profile of Ligands for RGD-binding Integrins.
Kapp TG; Rechenmacher F; Neubauer S; Maltsev OV; Cavalcanti-Adam EA; Zarka R; Reuning U; Notni J; Wester HJ; Mas-Moruno C; Spatz J; Geiger B; Kessler H
Sci Rep; 2017 Jan; 7():39805. PubMed ID: 28074920
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
